Regulation of Body Size and Growth Control
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Acute Knockdown of Depdc5 Leads to Synaptic Defects in Mtor-Related Epileptogenesis
Acute knockdown of Depdc5 leads to synaptic defects in mTOR-related epileptogenesis Antonio de Fusco, Maria Sabina Cerullo, Antonella Marte, Caterina Michetti, Alessandra Romei, Enrico Castroflorio, Stéphanie Baulac, Fabio Benfenati To cite this version: Antonio de Fusco, Maria Sabina Cerullo, Antonella Marte, Caterina Michetti, Alessandra Romei, et al.. Acute knockdown of Depdc5 leads to synaptic defects in mTOR-related epileptogenesis. Neurobiology of Disease, Elsevier, In press, 10.1016/j.nbd.2020.104822. hal-02498215 HAL Id: hal-02498215 https://hal.sorbonne-universite.fr/hal-02498215 Submitted on 4 Mar 2020 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Journal Pre-proof Acute knockdown of Depdc5 leads to synaptic defects in mTOR- related epileptogenesis Antonio De Fusco, Maria Sabina Cerullo, Antonella Marte, Caterina Michetti, Alessandra Romei, Enrico Castroflorio, Stephanie Baulac, Fabio Benfenati PII: S0969-9961(20)30097-8 DOI: https://doi.org/10.1016/j.nbd.2020.104822 Reference: YNBDI 104822 To appear in: Neurobiology of Disease Received date: 13 November 2019 Revised date: 2 February 2020 Accepted date: 26 February 2020 Please cite this article as: A. De Fusco, M.S. Cerullo, A. Marte, et al., Acute knockdown of Depdc5 leads to synaptic defects in mTOR-related epileptogenesis, Neurobiology of Disease(2020), https://doi.org/10.1016/j.nbd.2020.104822 This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. -
Using Drosophila to Discover Mechanisms Underlying Type 2 Diabetes Ronald W
© 2016. Published by The Company of Biologists Ltd | Disease Models & Mechanisms (2016) 9, 365-376 doi:10.1242/dmm.023887 REVIEW SUBJECT COLLECTION: TRANSLATIONAL IMPACT OF DROSOPHILA Using Drosophila to discover mechanisms underlying type 2 diabetes Ronald W. Alfa1,2,* and Seung K. Kim1,3,4,* ABSTRACT phenotypes (Dimas et al., 2014; Frayling and Hattersley, 2014; Mechanisms of glucose homeostasis are remarkably well conserved Renström et al., 2009). Nonetheless, major challenges remain in between the fruit fly Drosophila melanogaster and mammals. From translating GWAS associations into mechanistic and clinically the initial characterization of insulin signaling in the fly came the translatable insights (McCarthy et al., 2008). As discovery of identification of downstream metabolic pathways for nutrient storage disease-associated single-nucleotide polymorphisms (SNPs) and utilization. Defects in these pathways lead to phenotypes that are continues, these SNPs first need to be causally associated with analogous to diabetic states in mammals. These discoveries have individual genes. Once gene candidates are identified, the gold- stimulated interest in leveraging the fly to better understand the standard for characterizing the molecular mechanisms of disease genetics of type 2 diabetes mellitus in humans. Type 2 diabetes alleles and the role of individual genes in metabolic disease is results from insulin insufficiency in the context of ongoing insulin experimental interrogation in model organisms (McCarthy et al., resistance. Although genetic susceptibility is thought to govern the 2008). This task can present a formidable challenge considering that propensity of individuals to develop type 2 diabetes mellitus under SNPs might cause gain of function, loss of function or reflect tissue- appropriate environmental conditions, many of the human genes specific effects. -
DEPDC5 Takes a Second Hit in Familial Focal Epilepsy
DEPDC5 takes a second hit in familial focal epilepsy Matthew P. Anderson J Clin Invest. 2018;128(6):2194-2196. https://doi.org/10.1172/JCI121052. Commentary Loss-of-function mutations in a single allele of the gene encoding DEP domain–containing 5 protein (DEPDC5) are commonly linked to familial focal epilepsy with variable foci; however, a subset of patients presents with focal cortical dysplasia that is proposed to result from a second-hit somatic mutation. In this issue of the JCI, Ribierre and colleagues provide several lines of evidence to support second-hit DEPDC5 mutations in this disorder. Moreover, the authors use in vivo, in utero electroporation combined with CRISPR-Cas9 technology to generate a murine model of the disease that recapitulates human manifestations, including cortical dysplasia–like changes, focal seizures, and sudden unexpected death. This study provides important insights into familial focal epilepsy and provides a preclinical model for evaluating potential therapies. Find the latest version: https://jci.me/121052/pdf COMMENTARY The Journal of Clinical Investigation DEPDC5 takes a second hit in familial focal epilepsy Matthew P. Anderson Departments of Neurology and Pathology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA. Boston Children’s Hospital Intellectual and Developmental Disabilities Research Center, Boston, Massachusetts, USA. Program in Neuroscience, Harvard Medical School, Boston, Massachusetts, USA. These detailed genetic and biochemical correlations in the human tissues then led Loss-of-function mutations in a single allele of the gene encoding DEP them to design tests of causality in a mouse domain–containing 5 protein (DEPDC5) are commonly linked to familial model, in which they reconstituted many focal epilepsy with variable foci; however, a subset of patients presents with features of the human disorder. -
Genetic and Neural Mechanisms Regulating the Interaction
GENETIC AND NEURAL MECHANISMS REGULATING THE INTERACTION BETWEEN SLEEP AND METABOLISM IN DROSOPHILA MELANOGASTER by Maria E. Yurgel A Dissertation Submitted to the Faculty of The Charles E. Schmidt College of Science In Partial Fulfillment of the Requirements for the Degree of Doctor of Philosophy Florida Atlantic University Boca Raton, FL December 2018 Copyright 2018 by Maria Eduarda Yurgel ii GENETIC AND NEURAL MECHANISMS REGULATING THE INTERACTION BETWEEN SLEEP AND METABOLISM IN DROSOPHILAMELANOGASTER by Maria E. Yurgel This dissertation was prepared under the direction of the candidate's dissertation advisor, Dr. Alex C. Keene, Department of Biological Sciences, and has been approved by the members of her supervisory committee. It was submitted to the faculty of the Charles E. Schmidt College of Science and was accepted in partial fulfillmentof the requirements for the degree of Doctor of Philosophy. SUPERVISORY COMMITTEE: Z!--�•r<. �� --- Alex C. Keene, Ph.D. Disserta · n Advis ,,. Tanja Godenschwege, Ph.p Khaled Sobhan, Ph.D. Date� 7 Interim Dean, Graduate College 111 ACKNOWLEDGEMENTS I would like to express my gratitude for all my committee members for their guidance and support. First and foremost, I would like to thank my mentor, Dr. Alex Keene, for believing in my potential and giving me the opportunity to pursue my PhD in his laboratory. During these 5 years, I have been challenged to my limit and pushed to think, to be creative, and be productive. His passion and excitement for science fueled me to get out of my comfort zone, implement new techniques, and pursue questions that were not trivial. I am also greatly indebted to Dr. -
Supplementary Materials File Recent Advances In
1 Supplementary Materials file Appendix 1 Recent advances in neuropeptide signaling in Drosophila, from genes to physiology and behavior Dick R. Nässel1 and Meet Zandawala Brief overview of Drosophila neuropeptides and peptide hormones (Appendix to section 5) Contents 5. 1. Adipokinetic hormone (AKH) 5. 2. Allatostatin-A (Ast-A) 5. 3. Allatostatin-B (Ast-B), or myoinhibitory peptide (MIP) 5. 4. Allatostatin-C (Ast-C) 5. 5. Allatostatin-CC (Ast-CC) or allatostatin double C 5. 6. Bursicon and partner of bursicon, or bursicon a and b 5. 7. Capability (Capa), a precursor encoding periviscerokinins and a pyrokinin 5. 8. CCHamide-1 and CCHamide-2 are encoded by separate genes 5. 9. CNMamide 5. 10. Corazonin (CRZ) 5. 11. Crustacean cardioactive peptide (CCAP) 5. 12. Diuretic hormone 31 (DH31), or calcitonin-like diuretic hormone 5. 13. Diuretic hormone 44 (DH44) 5. 14. Ecdysis-triggering hormone (ETH) and pre-ecdysis-triggering hormone (PETH) 5. 15. Eclosion hormone (EH) 5. 16. FMRFamide (FMRFa), or extended FMRFamides 5. 17. Glycoprotein A2 (GPA2) and Glycoprotein B5 (GPB5) 5. 18. Insulin-like peptides (ILPs), encoded by multiple genes 5. 19. Ion-transport peptide (ITP) 5. 20. Leucokinin (LK) or kinins (insectakinins) 5. 21. Limostatin 2 5. 22. Myosuppressin (Dromyosuppressin, DMS) 5. 23. Natalisin 5. 24. Neuropeptide F (NPF) 5. 25. Neuropeptide-like precursors 5. 25. 1. Neuropeptide-like precursor 1 (NPLP1) 5. 25. 2. Neuropeptide-like precursor 2 (NPLP2) 5. 25. 3. Neuropeptide-like precursor 3 (NPLP3) 5. 25. 4. Neuropeptide-like precursor 4 (NPLP4) 5. 26. Orcokinin (OK) 5. 27. Pigment-dispersing factor (PDF) 5. -
The Genetics of Bipolar Disorder
Molecular Psychiatry (2008) 13, 742–771 & 2008 Nature Publishing Group All rights reserved 1359-4184/08 $30.00 www.nature.com/mp FEATURE REVIEW The genetics of bipolar disorder: genome ‘hot regions,’ genes, new potential candidates and future directions A Serretti and L Mandelli Institute of Psychiatry, University of Bologna, Bologna, Italy Bipolar disorder (BP) is a complex disorder caused by a number of liability genes interacting with the environment. In recent years, a large number of linkage and association studies have been conducted producing an extremely large number of findings often not replicated or partially replicated. Further, results from linkage and association studies are not always easily comparable. Unfortunately, at present a comprehensive coverage of available evidence is still lacking. In the present paper, we summarized results obtained from both linkage and association studies in BP. Further, we indicated new potential interesting genes, located in genome ‘hot regions’ for BP and being expressed in the brain. We reviewed published studies on the subject till December 2007. We precisely localized regions where positive linkage has been found, by the NCBI Map viewer (http://www.ncbi.nlm.nih.gov/mapview/); further, we identified genes located in interesting areas and expressed in the brain, by the Entrez gene, Unigene databases (http://www.ncbi.nlm.nih.gov/entrez/) and Human Protein Reference Database (http://www.hprd.org); these genes could be of interest in future investigations. The review of association studies gave interesting results, as a number of genes seem to be definitively involved in BP, such as SLC6A4, TPH2, DRD4, SLC6A3, DAOA, DTNBP1, NRG1, DISC1 and BDNF. -
Stranded Breaks in Drosophila Youheng Wei1,2†, Lucia Bettedi1†, Chun-Yuan Ting1, Kuikwon Kim1, Yingbiao Zhang1, Jiadong Cai2, Mary a Lilly1*
RESEARCH ARTICLE The GATOR complex regulates an essential response to meiotic double- stranded breaks in Drosophila Youheng Wei1,2†, Lucia Bettedi1†, Chun-Yuan Ting1, Kuikwon Kim1, Yingbiao Zhang1, Jiadong Cai2, Mary A Lilly1* 1Cell Biology and Neurobiology Branch, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, United States; 2College of Bioscience and Biotechnology, Yangzhou University, Yangzhou, China Abstract The TORC1 regulator GATOR1/SEACIT controls meiotic entry and early meiotic events in yeast. However, how metabolic pathways influence meiotic progression in metazoans remains poorly understood. Here we examine the role of the TORC1 regulators GATOR1 and GATOR2 in the response to meiotic double-stranded breaks (DSB) during Drosophila oogenesis. We find that in mutants of the GATOR2 component mio, meiotic DSBs trigger the constitutive downregulation of TORC1 activity and a permanent arrest in oocyte growth. Conversely, in GATOR1 mutants, high TORC1 activity results in the delayed repair of meiotic DSBs and the hyperactivation of p53. Unexpectedly, we found that GATOR1 inhibits retrotransposon expression in the presence of meiotic DSBs in a pathway that functions in parallel to p53. Thus, our studies have revealed a link between oocyte metabolism, the repair of meiotic DSBs and retrotransposon expression. DOI: https://doi.org/10.7554/eLife.42149.001 *For correspondence: [email protected] Introduction †These authors contributed We are interested in understanding how metabolism impacts meiotic progression during oogenesis. equally to this work Target of Rapamycin Complex 1 (TORC1) is a multi-protein complex that functions as a master regu- lator of metabolism (Loewith and Hall, 2011; Laplante and Sabatini, 2012a; Jewell and Guan, Competing interests: The 2013). -
Epileptic Spasms Are a Feature of DEPDC5 Mtoropathy
Epileptic spasms are a feature of DEPDC5 mTORopathy Gemma L. Carvill, PhD ABSTRACT Douglas E. Crompton, Objective: To assess the presence of DEPDC5 mutations in a cohort of patients with epileptic PhD, MBBS spasms. Brigid M. Regan, BSc Methods: We performed DEPDC5 resequencing in 130 patients with spasms, segregation anal- (Hons) ysis of variants of interest, and detailed clinical assessment of patients with possibly and likely Jacinta M. McMahon, pathogenic variants. BSc (Hons) DEPDC5 Julia Saykally Results: We identified 3 patients with variants in in the cohort of 130 patients with DEPDC5 Matthew Zemel, BS spasms. We also describe 3 additional patients with alterations and epileptic spasms: 2 Amy L. Schneider, MGen from a previously described family and a third ascertained by clinical testing. Overall, we describe DEPDC5 Couns 6 patients from 5 families with spasms and variants; 2 arose de novo and 3 were Leanne Dibbens, PhD familial. Two individuals had focal cortical dysplasia. Clinical outcome was highly variable. Katherine B. Howell, Conclusions: While recent molecular findings in epileptic spasms emphasize the contribution of de MBBS (Hons), novo mutations, we highlight the relevance of inherited mutations in the setting of a family history BMedSc of focal epilepsies. We also illustrate the utility of clinical diagnostic testing and detailed pheno- Simone Mandelstam, typic evaluation in characterizing the constellation of phenotypes associated with DEPDC5 alter- MBChB ations. We expand this phenotypic spectrum to include epileptic spasms, aligning DEPDC5 Richard J. Leventer, epilepsies more with the recognized features of other mTORopathies. Neurol Genet 2015;1:e17; MBBS, PhD doi: 10.1212/NXG.0000000000000016 A. -
Peninsula Laboratories International, Inc
PENINSULA LABORATORIES INTERNATIONAL, INC. ProductNumberName Amount Unit H-4952.0010 ([125I]-Tyr)-Angiotensin II, CE-marked, Liquid 10 µCi H-4954.0010 ([125I]-Tyr0)-Bradykinin, CE-marked, Liquid 10 µCi H-4956.0010 ([125I]-Tyr)-Calcitonin (salmon I), CE-marked, Liquid 10 µCi H-4958.0010 ([125I]-Tyr0)-a-CGRP (mouse, rat), CE-marked, Liquid 10 µCi H-4962.0010 ([125I]-Tyr0)-CRF (human, mouse, rat), CE-marked, Liquid 10 µCi H-4964.0010 ([125I]-Tyr)-Endothelin-1 (human, bovine, dog, mouse, porcine, rat), CE-marked, Liquid 10 µCi H-4966.0010 ([125I]-Tyr)-GLP-1 (7-36) amide (human, bovine, guinea pig, mouse, rat), CE-marked, Liquid 10 µCi H-4968.0010 ([125I]-Tyr)-(Des-Gly10,D-Leu6,Pro-NHEt9)-LHRH, CE-marked, Liquid 10 µCi H-4972.0010 ([125I]-Tyr)-(Des-Gly10,D-Trp6,Pro-NHEt9)-LHRH, CE-marked, Liquid 10 µCi H-4974.0010 ([125I]-Tyr)-Orexin A (human, bovine, canine, mouse, ovine, porcine, rat), CE-marked, Liquid 10 µCi H-4976.0010 ([125I]-Tyr)-Oxytocin, CE-marked, Liquid 10 µCi H-4978.0010 ([125I]-Tyr0)-pTH (1-34) (human), CE-marked, Liquid 10 µCi H-5004.0010 ([125I]-Tyr)-ACTH (1-39) (mouse, rat), CE-marked, Liquid 10 µCi H-5006.0010 ([125I]-Tyr)-Atrial Natriuretic Factor (1-28) (mouse, rabbit, rat), CE-marked, Liquid 10 µCi H-5008.0010 ([125I]-Tyr0)-BNP-32 (human), CE-marked, Liquid 10 µCi H-5012.0010 ([125I]-Tyr)-b-Endorphin (human), CE-marked, Liquid 10 µCi H-5016.0010 ([125I]-Tyr)-Gastric Inhibitory Polypeptide (human), CE-marked, Liquid 10 µCi H-5018.0010 ([125I]-Tyr)-Pancreatic Polypeptide (human), CE-marked, Liquid 10 µCi H-5022.0010 ([125I]-Tyr)-Peptide -
Epigenetic Mechanisms Are Involved in the Oncogenic Properties of ZNF518B in Colorectal Cancer
Epigenetic mechanisms are involved in the oncogenic properties of ZNF518B in colorectal cancer Francisco Gimeno-Valiente, Ángela L. Riffo-Campos, Luis Torres, Noelia Tarazona, Valentina Gambardella, Andrés Cervantes, Gerardo López-Rodas, Luis Franco and Josefa Castillo SUPPLEMENTARY METHODS 1. Selection of genomic sequences for ChIP analysis To select the sequences for ChIP analysis in the five putative target genes, namely, PADI3, ZDHHC2, RGS4, EFNA5 and KAT2B, the genomic region corresponding to the gene was downloaded from Ensembl. Then, zoom was applied to see in detail the promoter, enhancers and regulatory sequences. The details for HCT116 cells were then recovered and the target sequences for factor binding examined. Obviously, there are not data for ZNF518B, but special attention was paid to the target sequences of other zinc-finger containing factors. Finally, the regions that may putatively bind ZNF518B were selected and primers defining amplicons spanning such sequences were searched out. Supplementary Figure S3 gives the location of the amplicons used in each gene. 2. Obtaining the raw data and generating the BAM files for in silico analysis of the effects of EHMT2 and EZH2 silencing The data of siEZH2 (SRR6384524), siG9a (SRR6384526) and siNon-target (SRR6384521) in HCT116 cell line, were downloaded from SRA (Bioproject PRJNA422822, https://www.ncbi. nlm.nih.gov/bioproject/), using SRA-tolkit (https://ncbi.github.io/sra-tools/). All data correspond to RNAseq single end. doBasics = TRUE doAll = FALSE $ fastq-dump -I --split-files SRR6384524 Data quality was checked using the software fastqc (https://www.bioinformatics.babraham. ac.uk /projects/fastqc/). The first low quality removing nucleotides were removed using FASTX- Toolkit (http://hannonlab.cshl.edu/fastxtoolkit/). -
Engineered Type 1 Regulatory T Cells Designed for Clinical Use Kill Primary
ARTICLE Acute Myeloid Leukemia Engineered type 1 regulatory T cells designed Ferrata Storti Foundation for clinical use kill primary pediatric acute myeloid leukemia cells Brandon Cieniewicz,1* Molly Javier Uyeda,1,2* Ping (Pauline) Chen,1 Ece Canan Sayitoglu,1 Jeffrey Mao-Hwa Liu,1 Grazia Andolfi,3 Katharine Greenthal,1 Alice Bertaina,1,4 Silvia Gregori,3 Rosa Bacchetta,1,4 Norman James Lacayo,1 Alma-Martina Cepika1,4# and Maria Grazia Roncarolo1,2,4# Haematologica 2021 Volume 106(10):2588-2597 1Department of Pediatrics, Division of Stem Cell Transplantation and Regenerative Medicine, Stanford School of Medicine, Stanford, CA, USA; 2Stanford Institute for Stem Cell Biology and Regenerative Medicine, Stanford School of Medicine, Stanford, CA, USA; 3San Raffaele Telethon Institute for Gene Therapy, Milan, Italy and 4Center for Definitive and Curative Medicine, Stanford School of Medicine, Stanford, CA, USA *BC and MJU contributed equally as co-first authors #AMC and MGR contributed equally as co-senior authors ABSTRACT ype 1 regulatory (Tr1) T cells induced by enforced expression of interleukin-10 (LV-10) are being developed as a novel treatment for Tchemotherapy-resistant myeloid leukemias. In vivo, LV-10 cells do not cause graft-versus-host disease while mediating graft-versus-leukemia effect against adult acute myeloid leukemia (AML). Since pediatric AML (pAML) and adult AML are different on a genetic and epigenetic level, we investigate herein whether LV-10 cells also efficiently kill pAML cells. We show that the majority of primary pAML are killed by LV-10 cells, with different levels of sensitivity to killing. Transcriptionally, pAML sensitive to LV-10 killing expressed a myeloid maturation signature. -
Epileptic Spasms Are a Feature of DEPDC5 Mtoropathy
Epileptic spasms are a feature of DEPDC5 mTORopathy Gemma L. Carvill, PhD ABSTRACT Douglas E. Crompton, Objective: To assess the presence of DEPDC5 mutations in a cohort of patients with epileptic PhD, MBBS spasms. Brigid M. Regan, BSc Methods: We performed DEPDC5 resequencing in 130 patients with spasms, segregation anal- (Hons) ysis of variants of interest, and detailed clinical assessment of patients with possibly and likely Jacinta M. McMahon, pathogenic variants. BSc (Hons) DEPDC5 Julia Saykally Results: We identified 3 patients with variants in in the cohort of 130 patients with DEPDC5 Matthew Zemel, BS spasms. We also describe 3 additional patients with alterations and epileptic spasms: 2 Amy L. Schneider, MGen from a previously described family and a third ascertained by clinical testing. Overall, we describe DEPDC5 Couns 6 patients from 5 families with spasms and variants; 2 arose de novo and 3 were Leanne Dibbens, PhD familial. Two individuals had focal cortical dysplasia. Clinical outcome was highly variable. Katherine B. Howell, Conclusions: While recent molecular findings in epileptic spasms emphasize the contribution of de MBBS (Hons), novo mutations, we highlight the relevance of inherited mutations in the setting of a family history BMedSc of focal epilepsies. We also illustrate the utility of clinical diagnostic testing and detailed pheno- Simone Mandelstam, typic evaluation in characterizing the constellation of phenotypes associated with DEPDC5 alter- MBChB ations. We expand this phenotypic spectrum to include epileptic spasms, aligning DEPDC5 Richard J. Leventer, epilepsies more with the recognized features of other mTORopathies. Neurol Genet 2015;1:e17; MBBS, PhD doi: 10.1212/NXG.0000000000000016 A.